Frequent deletion of 3p21.1 region carrying semaphorin 3G and aberrant expression of the genes participating in semaphorin signaling in the epithelioid type of malignant mesothelioma cells

International Journal of Oncology

Volumn 39, Issue 6, 2011, Pages 1365-1374

  Yoshikawa, Yoshie ^a   Sato, Ayuko ^a   Tsujimura, Tohru ^a   Morinaga, Tomonori ^a   Fukuoka, Kazuya ^a   Yamada, Shusai ^a   Murakami, Aki ^a   Kondo, Nobuyuki ^a   Matsumoto, Seiji ^a   Okumura, Yoshitomo ^a,b   Tanaka, Fumihiro ^a   Hasegawa, Seiki ^a   Hashimoto Tamaoki, Tomoko ^a   Nakano, Takashi ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

^b Itami City Hospital   (Japan)

Author keywords

3p21.1 deletion; Class 3 semaphorin; Epithelioid type; Malignant mesothelioma; Vascular endothelial growth factor A

Indexed keywords

COMPLEMENTARY DNA; NEUROPILIN; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; SEMAPHORIN; SEMAPHORIN 3B; SEMAPHORIN 3F; SEMAPHORIN 3G; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN A;

ADULT; AGED; ALLELE; ARTICLE; CANCER CELL CULTURE; CELL HYPERPLASIA; CHROMOSOME 16P; CHROMOSOME 16P13; CHROMOSOME 1P; CHROMOSOME 22Q; CHROMOSOME 3P; CHROMOSOME 3P21; CHROMOSOME 4Q; CHROMOSOME 9P; CHROMOSOME 9P21; CLINICAL ARTICLE; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; DOWN REGULATION; EPITHELIOID CELL; FEMALE; GENE DELETION; GENE EXPRESSION; GENE LOSS; HETEROZYGOTE; HUMAN; HUMAN CELL; MALE; MALIGNANT MESOTHELIOMA; MESOTHELIUM CELL; PRIORITY JOURNAL; PROTEIN BINDING; SIGNAL TRANSDUCTION;

CELL LINE, TRANSFORMED; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 3; CLUSTER ANALYSIS; COMPARATIVE GENOMIC HYBRIDIZATION; GENE DOSAGE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LOSS OF HETEROZYGOSITY; MESOTHELIOMA; SEMAPHORINS; SIGNAL TRANSDUCTION;

EID: 80054808016     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.1158     Document Type: Article

References (45)

1. Selikoff IJ, Hammond EC and Seidman H: Latency of asbestos disease among insulation workers in the United States and Canada. Cancer 46: 2736-2740, 1980. (Pubitemid 11210245)
2. Kurumatani N and Tomioka K: (Epidemiology of pleural mesothelioma in Japan). Nippon Geka Gakkai Zasshi 110: 320-325, 2009.
3. Stevens MW, Leong AS, Fazzalari NL, et al.: Cytopathology of malignant mesothelioma: a stepwise logistic regression analysis. Diagn Cytopathol 8: 333-341, 1992.
4. Nojiri S, Gemba K, Aoe K, et al.: Survival and prognostic factors in malignant pleural mesothelioma: a retrospective study of 314 patients in the west part of Japan. Jpn J Clin Oncol 41: 32-39, 2011.
5. Neragi-Miandoab S: Multimodality approach in management of malignant pleural mesothelioma. Eur J Cardiothorac Surg 29: 14-19, 2006.
6. Zanazzi C, Hersmus R, Veltman IM, et al.: Gene expression profiling and gene copy-number changes in malignant mesothelioma cell lines. Genes Chromosomes Cancer 46: 895-908, 2007. (Pubitemid 47435019)
7. Factor RE, Dal Cin P, Fletcher JA and Cibas ES: Cytogenetics and fluorescence in situ hybridization as adjuncts to cytology in the diagnosis of malignant mesothelioma. Cancer 117: 247-253, 2009.
8. Krismann M, Müller KM, Jaworska M and Johnen G: Molecular cytogenetic differences between histological subtypes of malignant mesotheliomas: DNA cytometry and comparative genomic hybridization of 90 cases. J Pathol 197: 363-371, 2002. (Pubitemid 34778307)
9. Taniguchi T, Karnan S, Fukui T, et al.: Genomic profiling of malignant pleural mesothelioma with array-based comparative genomic hybridization shows frequent non-random chromosomal alteration regions including JUN amplification on 1p32. Cancer Sci 98: 438-446, 2007. (Pubitemid 46195618)
10. Cheng JQ, Jhanwar SC, Klein WM, et al.: p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma. Cancer Res 54: 5547-5551, 1994.
11. Xio S, Li D, Vijg J, Sugarbaker DJ, Corson JM and Fletcher JA: Codeletion of p15 and p16 in primary malignant mesothelioma. Oncogene 11: 511-515, 1995.
12. Sekido Y, Pass HI, Bader S, et al.: Neurofibromatosis type 2 (NF2) gene is somatically mutated in mesothelioma but not in lung cancer. Cancer Res 55: 1227-1231, 1995.
13. Bianchi AB, Mitsunaga SI, Cheng JQ, et al.: High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas. Proc Natl Acad Sci USA 92: 10854-10858, 1995.
14. Sekido Y, Bader S, Latif F, et al.: Human semaphorins A(V) and IV reside in the 3p21.3 small cell lung cancer deletion region and demonstrate distinct expression patterns. Proc Natl Acad Sci USA 93: 4120-4125, 1996. (Pubitemid 26146727)
15. Lerman MI and Minna JD: The 630-kb lung cancer homozygous deletion region on human chromosome 3p21.3: identification and evaluation of the resident candidate tumor suppressor genes. The International Lung Cancer Chromosome 3p21.3 Tumor Suppressor Gene Consortium. Cancer Res 60: 6116-6133, 2000.
16. Hesson LB, Cooper WN and Latif F: Evaluation of the 3p21.3 tumour-suppressor gene cluster. Oncogene 26: 7283-7301, 2007. (Pubitemid 350115980)
17. Murthy SS and Testa JR: Asbestos, chromosomal deletions, and tumor suppressor gene alterations in human malignant mesothelioma. J Cell Physiol 180: 150-157, 1999. (Pubitemid 29297191)
18. Strizzi L, Catalano A, Vianale G, et al.: Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. J Pathol 193: 468-475, 2001. (Pubitemid 32266815)
19. Hirayama N, Tabata C, Tabata R, et al.: Pleural effusion VEGF levels as a prognostic factor of malignant pleural mesothelioma. Respir Med 105: 137-142, 2011.
20. Yasumitsu A, Tabata C, Tabata R, et al.: Clinical significance of serum vascular endothelial growth factor in malignant pleural mesothelioma. J Thorac Oncol 5: 479-483, 2010.
21. Filho AL, Baltazar F, Bedrossian C, Michael C and Schmitt FC: Immunohistochemical expression and distribution of VEGFR-3 in malignant mesothelioma. Diagn Cytopathol 35: 786-791, 2007. (Pubitemid 350250764)
22. Bielenberg DR, Pettaway CA, Takashima S and Klagsbrun M: Neuropilins in neoplasms: expression, regulation, and function. Exp Cell Res 312: 584-593, 2006. (Pubitemid 43290335)
23. Soker S, Takashima S, Miao HQ, Neufeld G and Klagsbrun M: Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 92: 735-745, 1998. (Pubitemid 28155313)
24. Miao HQ, Soker S, Feiner L, Alonso JL, Raper JA and Klagsbrun M: Neuropilin-1 mediates collapsin-1/semaphorin III inhibition of endothelial cell motility: functional competition of collapsin-1 and vascular endothelial growth factor-165. J Cell Biol 146: 233-242, 1999.
25. Gaur P, Bielenberg DR, Samuel S, et al.: Role of class 3 semaphorins and their receptors in tumor growth and angiogenesis. Clin Cancer Res 15: 6763-6770, 2009.
26. Serini G, Maione F, Giraudo E and Bussolino F: Semaphorins and tumor angiogenesis. Angiogenesis 12: 187-193, 2009.
27. Tamagnone L, Artigiani S, Chen H, et al.: Plexins are a large family of receptors for transmembrane, secreted, and GPI-anchored semaphorins in vertebrates. Cell 99: 71-80, 1999. (Pubitemid 29468631)
28. Neufeld G and Kessler O: The semaphorins: versatile regulators of tumour progression and tumour angiogenesis. Nat Rev Cancer 8: 632-645, 2008.
29. Guttmann-Raviv N, Shraga-Heled N, Varshavsky A, Guimaraes-Sternberg C, Kessler O and Neufeld G: Semaphorin-3A and semaphorin-3F work together to repel endothelial cells and to inhibit their survival by induction of apoptosis. J Biol Chem 282: 26294-26305, 2007. (Pubitemid 47443814)
30. Kigel B, Varshavsky A, Kessler O and Neufeld G: Successful inhibition of tumor development by specific class-3 semaphorins is associated with expression of appropriate semaphorin receptors by tumor cells. PLoS One 3: e3287, 2008.
31. Toyofuku T, Zhang H, Kumanogoh A, et al.: Dual roles of Sema6D in cardiac morphogenesis through region-specific association of its receptor, plexin-A1, with offtrack and vascular endothelial growth factor receptor type 2. Genes Dev 18: 435-447, 2004. (Pubitemid 38316350)
32. Catalano A, Lazzarini R, Di Nuzzo S, Orciari S and Procopio A: The plexin-A1 receptor activates vascular endothelial growth factor-receptor 2 and nuclear factor-kappaB to mediate survival and anchorage-independent growth of malignant mesothelioma cells. Cancer Res 69: 1485-1493, 2009.
33. Sato A, Torii I, Tao LH, et al.: Establishment of a cell line from Japanese patient useful to generate an in vivo model for malignant pleural mesothelioma. Cancer Sci 102: 648-655, 2011.
34. Nannya Y, Sanada M, Nakazaki K, et al.: A robust algorithm for copy number detection using high-density oligonucleotide single nucleotide polymorphism genotyping arrays. Cancer Res 65: 6071-6079, 2005. (Pubitemid 40994391)
35. Andersen CL, Lamy P, Thorsen K, et al.: Frequent genomic loss at chr16p13.2 is associated with poor prognosis in colorectal cancer. Int J Cancer (In press).
36. Ivanov SV, Miller J, Lucito R, et al.: Genomic events associated with progression of pleural malignant mesothelioma. Int J Cancer 124: 589-599, 2009.
37. Luo Y, Raible D and Raper JA: Collapsin: a protein in brain that induces the collapse and paralysis of neuronal growth cones. Cell 75: 217-227, 1993. (Pubitemid 23320286)
38. Castro-Rivera E, Ran S, Brekken RA and Minna JD: Semaphorin 3B inhibits the phosphatidylinositol 3-kinase/Akt pathway through neuropilin-1 in lung and breast cancer cells. Cancer Res 68: 8295-8303, 2008.
39. Capparuccia L and Tamagnone L: Semaphorin signaling in cancer cells and in cells of the tumor microenvironment-two sides of a coin. J Cell Sci 122: 1723-1736, 2009.
40. Ferrara N: Vascular endothelial growth factor as a target for anticancer therapy. Oncologist 9 (Suppl 1): S2-S10, 2004.
41. Karayan-Tapon L, Wager M, Guilhot J, et al.: Semaphorin, neuropilin and VEGF expression in glial tumours: SEMA3G, a prognostic marker? Br J Cancer 99: 1153-1160, 2008.
42. Ito M, Ito G, Kondo M, et al.: Frequent inactivation of RASSF1A, BLU, and SEMA3B on 3p21.3 by promoter hypermethylation and allele loss in non-small cell lung cancer. Cancer Lett 225: 131-139, 2005. (Pubitemid 40732776)
43. Tischoff I, Markwarth A, Witzigmann H, et al.: Allele loss and epigenetic inactivation of 3p21.3 in malignant liver tumors. Int J Cancer 115: 684-689, 2005. (Pubitemid 40776690)
44. Ivanova AV, Ivanov SV, Prudkin L, et al.: Mechanisms of FUS1/TUSC2 deficiency in mesothelioma and its tumorigenic transcriptional effects. Mol Cancer 8: 91, 2009.
45. Catalano A, Caprari P, Rodilossi S, et al.: Cross-talk between vascular endothelial growth factor and semaphorin-3A pathway in the regulation of normal and malignant mesothelial cell proliferation. FASEB J 18: 358-360, 2004.